# US 2023/0132854 A1 · Mithramycin oxime derivatives having increased selectivity and anti-cancer activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0132854 A1
- Document ID: US20230132854A1
- Status: Published application
- Kind: A1
- Application number: 17/963,537
- Filed: 2022-10-11
- Published: 2023-05-04
- Earliest claimed: 2018-10-31
- Assignees: University of Kentucky Research Foundation
- Applicants: University of Kentucky Research Foundation
- Inventors: Jon S. Thorson; Jurgen Rohr; Markos Leggas; Joseph M. Eckenrode; Yinan Zhang; Yang Liu; Jianjun Zhang; Khaled Attia Shaaban Mahmoud
- Web page: https://patentgrep.com/patent/US20230132854A1

## CPC

- C07H 15/244: Anthraquinone radicals, e.g. sennosides
- A61P 35/00: Antineoplastic agents
- C07H 15/26: Acyclic or carbocyclic radicals, substituted by hetero rings
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds described herein are mithramycin (MTM) oxide (OX) derivatives. These compounds are useful for treatment of cancers and neuro-diseases.

## Claims

### Claim 1

A compound having the following formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of substituted or unsubstituted amino acid, amino acid dipeptide, acyl-amino acid, and acyl-amino acid dipeptide.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R is acyl-amino acid or acyl-amino acid dipeptide.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R is substituted acyl-amino acid or acyl-amino acid dipeptide.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R comprises a quinolone, a benzothizole, a phenyl, a pyridine, or an indol group.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R comprises an amino acid or amino acid dipeptide group, or a substituted amino acid or amino acid dipeptide group.

### Claim 6 (depends on 1)

A method of treating cancer or neuro-disease in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the compound of claim 1.

### Claim 7 (depends on 6)

The method of claim 6, wherein the method comprises treating Ewing sarcoma.

### Claim 8 (depends on 6)

The method of claim 6, wherein the method comprises treating prostate cancer.

### Claim 9 (depends on 6)

The method of claim 6, wherein the method comprises treating colon cancer.

### Claim 10 (depends on 6)

The method of claim 6, wherein the method comprises treating lung cancer.

### Claim 11 (depends on 6)

The method of claim 6, wherein the method comprises treating leukemia or lymphoma.

### Claim 12 (depends on 1)

A method for selectively modulating the activity of a target ETS transcription factor in a patient in need thereof, including administering to the patient a therapeutically effective amount of the compound of claim 1.
